Stifel Nicolaus Upgrades Inverness Medical Innovations (IMA) to Buy
More News related to BSTE
- Atticus Capital Boosts Stake in Inverness Medical (IMA) to 5.5%
- Piper Jaffray upgrades Biosite Incorporated (BSTE) to Market Perform
- Stifel Nicolaus Upgrades Inverness Medical Innovations (IMA) to Buy
- Largest $ Movers of Note - StreetInsider.com - 05/15/2007
- Inverness Medical Innovations (IMA) Raises Bid for Biosite (BSTE) to $92.50
More News related to CTEC
- China Agritech Receives Approval for NASDAQ Listing; New Symbol "CAGC"
- Cholestech (CTEC) Receives FDA CLIA Waived Status for New Combined Test Panel
- Stifel Nicolaus Upgrades Inverness Medical Innovations (IMA) to Buy
- StreetInsider.com Unusual 11 Mid-Day Movers 06/04/2007
- Inverness Medical Innovations (IMA) to Acquire Cholestech (CTEC)
More News related to IMA
- To Manage Weight Over the Holidays, Experts From Alere Say Enjoy, Indulge a Little and Don't Diet!
- OraSure Tech (OSUR) Settles Patent Infringement Suit with Inverness (IMA), Inverness Switzerland, and Church & Dwight (CHD)
- OraSure Tech (OSUR) Settles Patent Infringement Suit with Inverness (IMA), Inverness Switzerland, and Church & Dwight (CHD)
- Alere Secures Prestigious NCQA Accreditation for Wellness & Health Promotion
- OraSure Technologies Announces Settlement of Patent Infringement Lawsuit With Inverness and Church & Dwight
More News related to Upgrades
- Citi Initiates Coverage on AGA Medical (AGAM) with a Buy
- Dahlman Rose Initiates Coverage on RailAmerica (RA) with a Hold
- Goldman Sachs Resumes Autodesk (ADSK) at Neutral
- Stifel Nicolaus Initiates Coverage on Targa Resources Partners LP (NGLS) with a Hold
- Credit Suisse Restarts Coverage on MEMC Electronic Materials (WFR) with a Neutral
Stifel Nicolaus upgrades Inverness Medical Innovations (AMEX: IMA) from Hold to Buy with a $58 price target. The firm said, "We like both the strategic and financial impact of the Cholestech (NASDAQ: CTEC) acquisition that Inverness announced Monday morning. In addition, we have gained greater comfort with the proposed Biosite (Nasdaq: BSTE) deal, and the ability of Inverness to derive significant cost savings from the combined organizations."
Related Categories
UpgradesStocks Mentioned
-92.48
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
